

## COVID-19 Vaccine Information Brief

December 17, 2021

Changes to the document from the previous version are highlighted in yellow.

**IDPH offices will be closed December 23-24 and 31, 2021.**

**During this time, redistribution requests of COVID-19 vaccine will not be processed.**

**There will be no Vaccine Information Brief on December 24 or 31, 2021.**

### IMPORTANT/NEW COVID-19 Vaccine Information

- ACIP Recommends Pfizer and Moderna COVID Vaccines Over the J&J Vaccine
- COVID-19 Vaccine Allocation and Ordering Cadence
- COVID-19 Vaccine Quick Reference Guide
- Interim Clinical Considerations for Use of COVID-19 Vaccines - Updated
- Changes to the COVID-19 Vaccine OKE Administration Dashboard
- U.S. COVID-19 Vaccine Handling Toolkit
- Interactive COVID-19 Vaccine Conversations Module for Healthcare Professional
- Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training
- Moderna Webinars: Important Updates on the Booster Dose
- Pfizer Transition to Pfizer Tris COVID-19 Vaccine Formulation
- Pfizer Product Overview
- COVID-19 Call Center Holiday Hours & COVID-19 Vaccine Redistribution - **No Redistributions on December 23-24 or 31, 2021**
- Vaccine Expiration Date Resources
- Vaccination Supplies
- V-Safe After Vaccination Health Checker

### ACIP Recommends Pfizer and Moderna COVID Vaccines Over the J&J Vaccine

CDC is endorsing updated recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the prevention of COVID-19. **The ACIP recommends Pfizer and Moderna COVID vaccines should be given instead of the Johnson & Johnson vaccine, when possible and appropriate.** ACIP's unanimous recommendation followed a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the U.S. vaccine supply.

The reason for the update is due to a **new analysis** showing that the risk of a blood clotting condition after the J&J vaccine is still rare but greater than previously thought. In light of the new information, the CDC did a **risk-benefit analysis** showing that the mRNA vaccines by Pfizer and Moderna are safer and more effective than the J&J vaccine. **This is the vaccine safety monitoring processes working as intended.**

Given the current state of the pandemic both here and around the world, the ACIP reaffirmed that receiving any vaccine is better than being unvaccinated. Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson's COVID-19 vaccine.

Those who have received the J&J vaccine and have not experienced any symptoms of TTS ([listed here](#)) within 42 days are not at risk but do have protection against severe cases of COVID-19. An individual who has already received one dose of J&J vaccine could reasonably receive a second dose (just know there is a very rare, but real, risk). Or if an individual chooses not to receive the J&J vaccine again, they should receive a single dose of mRNA vaccine at least two months later. Not enough people have received a booster dose of the J&J vaccine to determine the risk of TTS after getting the vaccine as a booster.

---

## COVID-19 Vaccine Allocation and Ordering Cadence

The Department will continue to survey Local Public Health Agencies (LPHAs) biweekly to determine each county's desired COVID-19 vaccine allocation. The schedule below will be utilized for the remainder of 2021.

### December 2021

- **Week of December 27, 2021 - All COVID-19 Vaccines**
  - **Allocation Survey Sent - December 27, 2021**
  - **Allocation Survey Due Back to IDPH - December 27, 4:00 pm**
  - **Allocation Posted in IRIS - December 28, 2021**
  - **Allocation Due Back to IDPH in IRIS - December 28, 4:00 pm**
    - **Shortened time frame to allow vaccine orders to be placed prior to New Years holiday.**

Vaccine orders will not be delivered:

- December 23 - 27, 2021
  - December 30, 2021 - January 3, 2022
- 

## COVID-19 Quick Reference Guide

The quick reference guide provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. It is now updated with Pfizer Peds. For additional information and detailed clinical guidance go to the manufacturers' website and CDC's webpages listed on the guide.

Link to guide:

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-quick-reference-guide-2pages.pdf>

---

## Interim Clinical Considerations for Use of COVID-19 Vaccines - Updated

CDC has expanded COVID-19 booster recommendations to 16 and 17-year-olds. [Interim Clinical Considerations](#), the [Pfizer \(12 years of age and older\) Standing Orders](#), and the [Provider Requirements and Support page](#) have been updated to reflect this change.

As a reminder, current recommendations are as follows:

- For those who received a primary series of Pfizer-BioNTech COVID-19 Vaccine:
  - People **18 years and older should** receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after completing their Pfizer-BioNTech COVID-19 vaccine primary series. The Pfizer-BioNTech primary series consists of two doses, except for people who are moderately or severely immunocompromised, who should receive three doses as their primary series.
    - People **18 years and older with moderate or severe immunocompromise should** receive a booster dose at least 6 months after their additional (3<sup>rd</sup>) dose.
  - People **16 through 17 years old may** receive a Pfizer-BioNTech COVID-19 booster dose based on individual risks and benefits at least 6 months after completing their primary series of the Pfizer-BioNTech COVID-19 vaccine (two or three doses, as noted in the previous bullet). **Note:** Only the Pfizer-BioNTech COVID-19 vaccine may be administered for this booster dose; heterologous administration is not allowed for ages 16 through 17.
    - People **16 years through 17 years old with moderate or severe immunocompromise may** receive a booster dose at least 6 months after their additional (3<sup>rd</sup>) dose.
- For those who received a primary series of Moderna COVID-19 Vaccine:
  - People **18 years and older should** receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after their Moderna COVID-19 vaccine primary series. The Moderna primary series consists of two doses, except for people who are moderately or severely immunocompromised, who should receive three doses as their primary series.
  - People **18 years and older with moderate or severe immunocompromise should** receive a booster dose at least 6 months after their additional (3<sup>rd</sup>) dose.
- For those who received a primary dose of Janssen COVID-19 Vaccine:
  - People **18 years and older should** receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 2 months after receipt of the Janssen COVID-19 vaccine single-dose primary regimen.

## Changes to the Iowa COVID-19 Vaccine Administration Dashboard

Pediatric Pfizer (5-11) and Booster dose vaccine administration data were added to the [COVID-19 Vaccine Administration Dashboard](#) on December 8, 2021. These data had an impact on the total number of doses administered statewide. The Pfizer (5-11) vaccine data will impact the series initiating/completing two-dose vaccination measures as well as total vaccine series completed. The booster doses are defined as any additional dose after completion of a primary series. The booster doses will not have any impact on the total vaccine series completed data.

## U.S. COVID-19 Vaccine Handling Toolkit

The US COVID-19 Vaccine Handling Toolkit was first published in January 2021. With new and updated vaccine information, the toolkit has been revised to help ensure frontline practitioners have the most updated, relevant COVID-19 vaccine related information. As of November 2021, the toolkit has been revised to include information regarding booster doses, pediatric Pfizer-BioNTech vaccine preparation and beyond-use dating in pre-drawn syringes, and ways to avoid mix-ups with other vaccines.

- [COVID-19 Vaccine Handling Guides: Operational Considerations for Healthcare Practitioners](#)

---

## Interactive COVID-19 Vaccine Conversations Module for Healthcare Professionals

The Centers for Disease Control and Prevention (CDC) has developed the **Interactive COVID-19 Vaccine Conversations Module for Healthcare Professionals**. The tool includes:

- Tips for Having Effective Vaccine Conversations with Patients
- Vaccine Conversations in Practice: Case Scenarios

**Access and equip healthcare professionals with this free CDC resource today:**

<https://www.cdc.gov/vaccines/covid-19/hcp/conversations-module.html>

---

## Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training

Pfizer Vaccines US Medical Affairs continues to host daily *Medical Updates & Immunization Site Training for All Providers with a Focus on Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine for Children 5 through 11 Years of Age*.

- In addition to Medical Updates, sessions will focus on the Storage, Handling, & Administration for currently available vaccine presentations
- These sessions will be updated to reflect new information and changes that evolve. Such updates will be identified at the start of each session and further explained during each presentation.

Please click on the links below to join the sessions at the designated times.\*

Date & Time	Password
<a href="#">Attendee link – Mon December 27 – 3 PM ET</a>	dbEMTcK4c26
<a href="#">Attendee link – Tues December 28 – 12 PM ET</a>	47DiG6JXsgA

---

## Moderna Webinars: Important Updates on the Booster Dose

Moderna is offering a webinar for vaccination providers interested in learning more about the Moderna COVID-19 Vaccine booster dose, which has been authorized for emergency use in the United States.

Please visit this [link](#) to register for one of these available sessions.

- Dec 14th @ 11:00 AM PST
- Dec 15th @ 3:00 PM EST
- Dec 16th @ 12:00 PM EST
- Dec 17th @ 12:00 PM PST

Please note: Registration for each event closes 1 hour before the listed start time.

---

## Pfizer Transition to the new adult/adolescent Tris COVID-19 Vaccine

A new formulation of Pfizer vaccine for adults/adolescents will be available to Iowa healthcare providers. The formulation will have a distinctive **GRAY** cap and:


- Will be available in smaller 300-dose configurations
- **Does not** require diluent
- May be stored at 2-8°C (36-46°F) for up to 10 week; **DO NOT PLACE THE PRODUCT IN A REGULAR FREEZER**
- Can be used on individuals 12 years of age and older

Healthcare providers should utilize existing Pfizer formulations (1170 and 450 dose packs) to the greatest extent possible. **CDC recommends provider sites should ideally carry only one Pfizer adult formulation at a time.** In order to avoid mistakes during this **period of transition** when both products may be in circulation, these products should not be offered/administered at the same time.

## Ordering Availability

- CDC will review Iowa's progress and use of current Pfizer in-field inventory on a weekly basis to assess the need and ability to order the new Pfizer formulation.
- CDC will notify Iowa when the vaccine will be available to order for providers based on inventory levels of existing Pfizer 1170 and 450 dose packs.
  - Iowa will not be able to order until the current Pfizer inventory in the state is significantly reduced/utilized
- CDC will retire the current Pfizer 1170 packs ordering and transition to the new Pfizer formulation
  - Minimum Order Quantity will be 300 doses
- Health care providers should utilize existing Pfizer formulations (1170 and 450 dose packs) to the greatest extent possible.
- LPHAs and healthcare providers should collaborate to redistribute Pfizer COVID-19 vaccine inventory to reduce statewide vaccine inventory.
- CDC's intent is health care providers will only have two formulations of Pfizer COVID-19 vaccine in inventory
  - Adult/Adolescent Vaccine - 12 years of age and older (Gray Cap)
  - Pediatric Vaccine - 5 - 11 years (Orange Cap)

## Pfizer Product Overview

Description	Formulations		
	<i>Dilute Prior to Use</i>	<i>Do Not Dilute</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	12 years and older	5 to <12 years*
Vial Cap Color	PURPLE 	GRAY (Coming soon) 	ORANGE 
Dose	30 mcg	30 mcg	10 mcg
Injection Volume	0.3 mL	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	NO DILUTION	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90°C to -60°C)	9 months	6 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks

\*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS)

## COVID-19 Vaccine Redistribution

**The Iowa Department of Public Health will be closed December 23-24, 2021. During this time, redistribution requests of COVID-19 vaccine will not be processed.**

The [Vaccine Redistribution Policy and Process](#) and [Vaccine Redistribution Form](#) is required for each redistribution. Instructions for LPHAs to view provider IRIS inventory, along with COVID-19 Vaccine inventory maps, are posted to the HAN \*3 COVID-19 Vaccine folder under the \*1 Vaccine Inventory Maps. Questions regarding COVID-19 vaccine redistribution and the transfer of COVID-19 vaccine can be directed to 1-800-831-6293 ext. 1 or [COVID19Vaccine@idph.iowa.gov](mailto:COVID19Vaccine@idph.iowa.gov).

The redistribution of COVID-19 vaccines and the physical transfer of vaccine between COVID-19 vaccination providers **MUST ONLY** occur after IDPH approval and IRIS transfer is complete. Inventory adjustments or redistribution of COVID-19 vaccine without IDPH approval may result in the loss of COVID-19 vaccine provider status and removal of COVID-19 vaccines.

The following are requirements for the redistribution of COVID-19 vaccine:

- Redistribution will ONLY be allowed between IDPH approved COVID-19 vaccine providers
- **Redistribution MUST be completed prior to physically transferring COVID-19 vaccine**
- Redistribution must be completed before administration of COVID-19 vaccine
- Redistribution will require completion of the COVID-19 Vaccine Redistribution Form and prior approval by IDPH; IDPH will approve all requests within 24 hours
- Immunization Program staff will initiate the transfer of doses in the initiating organization's IRIS account, and will accept the transfer of doses in the receiving organization's IRIS account
- Transferring provider is responsible for the physical transfer of vaccine and ancillary supplies  
Receiving organization is required to document COVID-19 vaccine doses administered in IRIS

Questions regarding COVID-19 vaccine can be directed to 1-800-831-6293 ext. 1 or [COVID19Vaccine@idph.iowa.gov](mailto:COVID19Vaccine@idph.iowa.gov).

---

## Vaccine Expiration Date Resources

Always be sure to check the manufacturer's website to obtain the most up-to-date expiration dates for COVID-19 vaccines. This is necessary for J&J vaccine as well as Moderna and Pfizer COVID-19 vaccines. It is important for healthcare providers to update vaccine expiration dates in IRIS. Questions regarding IRIS vaccine inventory and adjusting expiration dates can be directed to the IRIS Helpdesk at 800-374-3958.

**For EUA COVID-19 vaccines that do not have a final expiration date, the CDC has set an expiration date of 12/31/2069 to serve as a *placeholder date*.** Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. This placeholder date, which is far in the future, is intended to serve as a prompt for the provider to check the latest expiry information on the manufacturer's website. **It is important for healthcare providers to update vaccine expiration dates in IRIS.**

**Janssen COVID-19 vaccine:** The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Call 1-800-565-4008, or
- Go to [www.vaxcheck.inj/](http://www.vaxcheck.inj/)

**Moderna COVID-19 vaccine:**

The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Go to [www.modernatx.com/covid19vaccine-eua/](http://www.modernatx.com/covid19vaccine-eua/)

**The new Pfizer Adult/Adolescent formulation (gray cap) and Pediatric COVID-19 vaccine (orange cap):**

- Pfizer does not have an expiration date look up tool for these vaccines
- Formulation does NOT have expiration printed on vial
- Instead, each vial has the lot number and date of manufacture printed on the label
- **Date on the label is NOT the expiration date**
- **Expiration date of the Pfizer pediatric COVID-19 vaccine is 6 months from the manufacturer date**
  - Example: A vial with a manufacture date of 8/2021 includes August. It does not start in September. Expiration date would be Jan 31, 2022.

CDC's [COVID-19 Vaccine Expiration Date Tracking Tool](#) can help providers keep track of the expiration date by lot number.

J&J/Janssen		Moderna		Pfizer	
Lot Number	Expiration	Lot Number	Expiration	Lot Number	Expiration
		016C21A	12/20/2021	EW0196	12/31/2021
212A21A	12/21/2021	086D21A	12/21/2021	EW0202	12/31/2021
213A21A	12/21/2021	021C21A	12/21/2021	EW0217	12/31/2021
1822786	2/6/2022	005C21A	12/22/2021	EW0191	12/31/2021
1822809	3/7/2022	025C21A	12/23/2021	FA6780	12/31/2021
215C21A	3/8/2022	087D21A	12/23/2021	FA7484	12/31/2021
1822811	3/20/2022	022C21A	12/23/2021	EW0198	12/31/2021
203F21A	3/21/2022	023C21A	12/24/2021	FA7483	12/31/2021
204F21A	3/22/2022	939894	12/25/2021	FC3180	1/31/2022
218C21A	4/9/2022	024C21A	12/26/2021	FD8448	1/31/2022
1855194	4/9/2022	027C21A	12/26/2021	EY0584	1/31/2022
211D21A	4/11/2022	035C21A	12/30/2021	FC3184	1/31/2022
213D21A	4/11/2022	040C21A	12/30/2021	FC3183	1/31/2022
1855191	4/11/2022	939895	12/30/2021	FD0809	1/31/2022
220C21A	4/11/2022	036C21A	1/1/2022	FC3181	1/31/2022
208D21A	4/24/2022	037C21A	1/2/2022	FK5127	1/31/2022
1855835	4/27/2022	939896	1/2/2022	FJ5682	1/31/2022
		045C21A	1/4/2022	FA7485	1/31/2022
		050C21A	1/6/2022	FC3182	1/31/2022
		055E21A	1/6/2022	FJ5683	1/31/2022
		048E21A	1/7/2022	30125BA	2/28/2022
		053C21A	1/9/2022	FD0810	2/28/2022
		057E21A	1/9/2022	FD7220	2/28/2022
		052C21A	1/10/2022	EY0581	2/28/2022
		001F21A	1/12/2022	FE3590	2/28/2022
		939900	1/12/2022	30145BA	2/28/2022
		076C21A	1/13/2022	30135BA	2/28/2022



	051E21A	1/14/2022	30130BA	2/28/2022
	077C21B	1/14/2022	FE3592	2/28/2022
	078C21A	1/15/2022	FJ6369	2/28/2022
	079C21A	1/16/2022	FL0007	2/28/2022
	019F21A	1/20/2022	FK9729	2/28/2022
	015F21A	1/20/2022	FL8095	2/28/2022
	006D21A	1/21/2022	FD7218	2/28/2022
	010D21A	1/21/2022	FK9896	2/28/2022
	020F21A	1/21/2022	FK9895	2/28/2022
	011D21A	1/22/2022	FK5618	2/28/2022
	048F21A	1/22/2022	FE3594	2/28/2022
	013F21A	1/22/2022	FM0698	2/28/2022
	012D21A	1/23/2022	EY0582	2/28/2022

## Vaccination Supplies

The State of Iowa has recently obtained a limited quantity of individual 25 Gauge 5/8 inch safety needles, 1cc syringes, and a supply of combination 1 inch safety needles and 1 CC syringes. These vaccination supplies are available upon request by Local Public Health Agencies. These supplies are intended to be a back-up resource, the vaccine ancillary kits delivered with the vaccine will have 1 or 1<sup>1/2</sup> inch needles, however IDPH is aware many prefer the 5/8 inch needles for the younger pediatric doses.

LPHAs should contact their [county emergency management coordinator](#) to request these supplies. County Emergency Managers will enter an individual WebEOC Mission for each LPHA requesting the needles and syringes.

## V-Safe After Vaccination Health Checker

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support. These web pages will be continuously updated with additional resources.

- V-safe information sheet and poster: Posted on the Vaccine webpage and available in 5 languages: English, Spanish, Korean, Vietnamese, and Simplified Chinese
- [V-safe after vaccination health checker website](#)
- [V-Safe Print Resources](#)
- [Vaccine Adverse Event Reporting System \(VAERS\)](#)